Prolactin-secreting adenomas (prolactinomas) are the most common secreting adenomas of the pituitary. Microprolactinomas (diameter <10 mm) are frequently diagnosed in women, whereas macroprolactinomas (maximum diameter ≥10 mm) are generally seen in men. Most macroprolactinomas measure between 10 and 40 mm. Giant prolactinomas, measuring >40 mm, are rare, accounting for only 1–5% of all prolactinomas. Although generally benign, giant prolactinomas are aggressive and invasive, extending into the suprasellar region and also involving the cavernous sinuses. The optic chiasm is frequently involved, which leads to visual damage, and patients occasionally suffer from ophthalmoplegia. Long-term (usually lifetime) therapy with high-dose dopamine agonists (cabergoline or bromocriptine), together with pituitary surgery in some cases and radiotherapy if required, can achieve biochemical remission, tumor control, and clinical improvement in most patients.

1.
Fernandez
A
,
Karavitaki
N
,
Wass
JA
.
Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)
.
Clin Endocrinol (Oxf)
.
2010
Mar
;
72
(
3
):
377
82
.
[PubMed]
0300-0664
2.
Colao
A
,
Sarno
AD
,
Cappabianca
P
,
Briganti
F
,
Pivonello
R
,
Somma
CD
, et al.
Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia
.
Eur J Endocrinol
.
2003
Mar
;
148
(
3
):
325
31
.
[PubMed]
0804-4643
3.
Gillam
MP
,
Molitch
ME
,
Lombardi
G
,
Colao
A
.
Advances in the treatment of prolactinomas
.
Endocr Rev
.
2006
Aug
;
27
(
5
):
485
534
.
[PubMed]
0163-769X
4.
Moraes
AB
,
Silva
CM
,
Vieira Neto
L
,
Gadelha
MR
.
Giant prolactinomas: the therapeutic approach
.
Clin Endocrinol (Oxf)
.
2013
Oct
;
79
(
4
):
447
56
.
[PubMed]
0300-0664
5.
Maiter
D
,
Delgrange
E
.
Therapy of endocrine disease: the challenges in managing giant prolactinomas
.
Eur J Endocrinol
.
2014
Jun
;
170
(
6
):
R213
27
.
[PubMed]
0804-4643
6.
Delgrange
E
,
Raverot
G
,
Bex
M
,
Burman
P
,
Decoudier
B
,
Devuyst
F
, et al.
Giant prolactinomas in women
.
Eur J Endocrinol
.
2013
Nov
;
170
(
1
):
31
8
.
[PubMed]
0804-4643
7.
Shimon
I
,
Sosa
E
,
Mendoza
V
,
Greenman
Y
,
Tirosh
A
,
Espinosa
E
, et al.
Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas
.
Pituitary
.
2016
Aug
;
19
(
4
):
429
36
.
[PubMed]
1386-341X
8.
Melmed
S
,
Casanueva
FF
,
Hoffman
AR
,
Kleinberg
DL
,
Montori
VM
,
Schlechte
JA
, et al.;
Endocrine Society
.
Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline
.
J Clin Endocrinol Metab
.
2011
Feb
;
96
(
2
):
273
88
.
[PubMed]
0021-972X
9.
Arshad
MF
,
Arambewela
M
,
Debono
M
.
Atypical giant prolactinoma with frontal lobe manifestations
.
BMJ Case Rep
.
2018
Sep
;
2018
:
bcr-2018-226982
.
[PubMed]
1757-790X
10.
Grozinsky-Glasberg
S
,
Shimon
I
.
Unusual clinical presentations of giant prolactinomas
.
Pituitary
.
2011
Dec
;
14
(
4
):
340
4
.
[PubMed]
1386-341X
11.
Brisman
MH
,
Fetell
MR
,
Post
KD
.
Reversible dementia due to macroprolactinoma. Case report
.
J Neurosurg
.
1993
Jul
;
79
(
1
):
135
7
.
[PubMed]
0022-3085
12.
Deepak
D
,
Daousi
C
,
Javadpour
M
,
MacFarlane
IA
.
Macroprolactinomas and epilepsy
.
Clin Endocrinol (Oxf)
.
2007
Apr
;
66
(
4
):
503
7
.
[PubMed]
0300-0664
13.
Siddiqui
A
,
Chew
N
,
Miszkiel
K
.
Case report: unusual orbital invasion by a giant prolactinoma
.
Br J Radiol
.
2008
Nov
;
81
(
971
):
e259
62
.
[PubMed]
0007-1285
14.
Alkatari
S
,
Aljohani
N
.
Obstructive hydrocephalus, fifth nerve and hypothalamus involvement: acute presentation of a giant prolactinoma
.
Clin Med Insights Case Rep
.
2012
;
5
:
115
8
.
[PubMed]
1179-5476
15.
Shrivastava
RK
,
Arginteanu
MS
,
King
WA
,
Post
KD
.
Giant prolactinomas: clinical management and long-term follow up
.
J Neurosurg
.
2002
Aug
;
97
(
2
):
299
306
.
[PubMed]
0022-3085
16.
Corsello
SM
,
Ubertini
G
,
Altomare
M
,
Lovicu
RM
,
Migneco
MG
,
Rota
CA
, et al.
Giant prolactinomas in men: efficacy of cabergoline treatment
.
Clin Endocrinol (Oxf)
.
2003
May
;
58
(
5
):
662
70
.
[PubMed]
0300-0664
17.
Shimon
I
,
Benbassat
C
,
Hadani
M
.
Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men
.
Eur J Endocrinol
.
2007
Feb
;
156
(
2
):
225
31
.
[PubMed]
0804-4643
18.
Acharya
SV
,
Gopal
RA
,
Menon
PS
,
Bandgar
TR
,
Shah
NS
.
Giant prolactinoma and effectiveness of medical management
.
Endocr Pract
.
2010
Jan-Feb
;
16
(
1
):
42
6
.
[PubMed]
1530-891X
19.
Garibi
J
,
Pomposo
I
,
Villar
G
,
Gaztambide
S
.
Giant pituitary adenomas: clinical characteristics and surgical results
.
Br J Neurosurg
.
2002
Apr
;
16
(
2
):
133
9
.
[PubMed]
0268-8697
20.
Madsen
H
,
Borges
TM
,
Knox
AJ
,
Michaelis
KA
,
Xu
M
,
Lillehei
KO
, et al.
Giant pituitary adenomas: pathologic-radiographic correlations and lack of role for p53 and MIB-1 labeling
.
Am J Surg Pathol
.
2011
Aug
;
35
(
8
):
1204
13
.
[PubMed]
0147-5185
21.
Espinosa
E
,
Sosa
E
,
Mendoza
V
,
Ramírez
C
,
Melgar
V
,
Mercado
M
.
Giant prolactinomas: are they really different from ordinary macroprolactinomas?
Endocrine
.
2016
Jun
;
52
(
3
):
652
9
.
[PubMed]
1355-008X
22.
Huang
HY
,
Lin
SJ
,
Zhao
WG
,
Wu
ZB
.
Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review
.
Metab Brain Dis
.
2018
Jun
;
33
(
3
):
969
76
.
[PubMed]
0885-7490
23.
Huang
HY
,
Zhai
W
,
Tang
H
,
Hui
GZ
,
Wu
ZB
.
Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas
.
Endocrine
.
2018
Nov
;
62
(
2
):
464
9
. ;
Epub ahead of print
.
[PubMed]
1355-008X
24.
Chng
E
,
Dalan
R
.
Pituitary apoplexy associated with cabergoline therapy
.
J Clin Neurosci
.
2013
Dec
;
20
(
12
):
1637
43
.
[PubMed]
0967-5868
25.
Česák
T
,
Poczos
P
,
Adamkov
J
,
Náhlovský
J
,
Kašparová
P
,
Gabalec
F
, et al.
Medically induced CSF rhinorrhea following treatment of macroprolactinoma: case series and literature review
.
Pituitary
.
2018
Dec
;
21
(
6
):
561
70
. ;
Epub ahead of print
.
[PubMed]
1386-341X
26.
Andujar-Plata
P
,
Villar-Taibo
R
,
Ballesteros-Pomar
MD
,
Vidal-Casariego
A
,
Pérez-Corral
B
,
Cabezas-Agrícola
JM
, et al.
Long-term outcome of multimodal therapy for giant prolactinomas
.
Endocrine
.
2017
Jan
;
55
(
1
):
231
8
.
[PubMed]
1355-008X
27.
Bevan
JS
,
Adams
CB
,
Burke
CW
,
Morton
KE
,
Molyneux
AJ
,
Moore
RA
, et al.
Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including pre-operative bromocriptine therapy
.
Clin Endocrinol (Oxf)
.
1987
May
;
26
(
5
):
541
56
.
[PubMed]
0300-0664
28.
Mohan
N
,
Chia
YY
,
Goh
GH
,
Ting
E
,
Teo
K
,
Yeo
TT
.
Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective
.
BMJ Case Rep
.
2017
Nov
;
2017
:
bcr-2017-220971
.
[PubMed]
1757-790X
29.
Wu
ZB
,
Yu
CJ
,
Su
ZP
,
Zhuge
QC
,
Wu
JS
,
Zheng
WM
.
Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up
.
J Neurosurg
.
2006
Jan
;
104
(
1
):
54
61
.
[PubMed]
0022-3085
30.
Lim
S
,
Shahinian
H
,
Maya
MM
,
Yong
W
,
Heaney
AP
.
Temozolomide: a novel treatment for pituitary carcinoma
.
Lancet Oncol
.
2006
Jun
;
7
(
6
):
518
20
.
[PubMed]
1470-2045
31.
Syro
LV
,
Uribe
H
,
Penagos
LC
,
Ortiz
LD
,
Fadul
CE
,
Horvath
E
, et al.
Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm
.
Clin Endocrinol (Oxf)
.
2006
Oct
;
65
(
4
):
552
3
.
[PubMed]
0300-0664
32.
Almalki
MH
,
Aljoaib
NN
,
Alotaibi
MJ
,
Aldabas
BS
,
Wahedi
TS
,
Ahmad
MM
, et al.
Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review
.
Hormones (Athens)
.
2017
Apr
;
16
(
2
):
139
49
.
[PubMed]
2520-8721
33.
Bengtsson
D
,
Schrøder
HD
,
Berinder
K
,
Maiter
D
,
Hoybye
C
,
Ragnarsson
O
, et al.
Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide
.
Endocrine
.
2018
Sep
;
•••
: ;
Epub ahead of print
.
[PubMed]
1355-008X
34.
Shimon
I
,
Benbassat
C
,
Tzvetov
G
,
Grozinsky-Glasberg
S
.
Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression
.
Pituitary
.
2011
Mar
;
14
(
1
):
11
5
.
[PubMed]
1386-341X
35.
Prior
JC
,
Cox
TA
,
Fairholm
D
,
Kostashuk
E
,
Nugent
R
.
Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen
.
J Clin Endocrinol Metab
.
1987
Feb
;
64
(
2
):
391
4
.
[PubMed]
0021-972X
36.
Vroonen
L
,
Lancellotti
P
,
Garcia
MT
,
Dulgheru
R
,
Rubio-Almanza
M
,
Maiga
I
, et al.
Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia
.
Endocrine
.
2017
Jan
;
55
(
1
):
239
45
.
[PubMed]
1355-008X
37.
De Sousa
SM
,
Chapman
IM
,
Falhammar
H
,
Torpy
DJ
.
Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists
.
Endocrine
.
2017
Feb
;
55
(
2
):
618
24
.
[PubMed]
1355-008X
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.